



Intraductal oncocytic papillary neoplasm (IOPN): two case reports and review of the literature

Lorenzo Innocenti^{1^}, Maria Isabella Rotondo^{2^}, Francescamaria Donati^{3^}, Ugo Boggi⁴, Daniela Campani^{1^}

¹Division of Pathology, Department of Surgical, Medical, Molecular Pathology and Critical Care Medicine, Pisa University Hospital, Pisa, Italy;

²Department of Surgical Pathology, University Hospital of Pisa, Pisa, Italy; ³Division of Diagnostic and Interventional Radiology, University Hospital of Pisa, Pisa, Italy; ⁴Division of General and Transplant Surgery, University of Pisa, Pisa, Italy

Contributions: (I) Conception and design: L Innocenti, MI Rotondo, D Campani; (II) Administrative support: None; (III) Provision of study materials or patients: MI Rotondo, F Donati, U Boggi, D Campani; (IV) Collection and assembly of data: L Innocenti; (V) Data analysis and interpretation: L Innocenti, MI Rotondo, F Donati, D Campani; (VI) Manuscript writing: All Authors; (VII) Final approval of manuscript: All Authors.

Correspondence to: Lorenzo Innocenti. Division of Pathology, Department of Surgical, Medical, Molecular Pathology and Critical Care Medicine, Pisa University Hospital, 56124 Pisa, Italy. Email: innocenti693@gmail.com.

Background: Intraductal oncocytic papillary neoplasms (IOPNs) place at the oncocytic extreme of the intraductal pancreatic neoplasm spectrum and display typical morphological features. Their identification in 1996 by Adsay *et al.* has been followed by a growing number of cases, paving the way for a deeper understanding of this underestimated entity. Contrarily to intraductal papillary mucinous neoplasms (IPMNs), most IOPNs run an indolent course and surgery is usually curative. Pancreatic IOPNs tend to develop from the main pancreatic duct (MPD) and their diagnosis is either incidental or subsequent to mass-related symptoms. Up to 30% of cases show concomitant areas of minimal stromal invasion and loco-regional or systemic spread are confined to a minority of cases. Biological hallmarks of IOPNs are being identified, including recurrent kinase gene rearrangements. Morphological and biological traits of IOPNs seem to overlap with those of other malignancies. A deeper understanding of these entities is needed in order to shed light upon the nature of pancreato-biliary oncocytic neoplasms. This case report describes two patients with a diagnosis of IOPN—one of them accounting for the largest IOPN ever described—and provides a brief review of recent discoveries on the subject.

Case Description: We describe two cases of IOPN occurring in adult male patients, respectively in their 60s and 70s. Both patients had unremarkable clinical history. In case 1 the diagnosis was coincidental to a right renal colic; case 2 complained a right lumbar pain radiating to the homolateral groin. In both cases imaging analyses revealed a voluminous pancreatic mass, posing the indication to laparoscopic pancreatectomy. Gross and histological features were consistent with the diagnosis of IOPN. Surgical margin were free from disease and the patient did not undergo further treatment. After a 10- and 7-month follow-up respectively, patients did not experience relapse.

Conclusions: Recent immunohistochemical (IHC) and molecular data reveal unique characteristics of IOPNs, highlighting the substantial differences from IPMNs. Further research is needed in order to identify novel prognostic and predictive markers applicable to oncocytic neoplasms of the pancreato-biliary tract.

Keywords: Intraductal oncocytic papillary neoplasm (IOPN); intraductal papillary mucinous neoplasm (IPMN); case report; pancreas; immunohistochemistry

Submitted Aug 12, 2022. Accepted for publication Dec 20, 2022. Published online Mar 02, 2023.

doi: [10.21037/tcr-22-2029](https://doi.org/10.21037/tcr-22-2029)

View this article at: <https://dx.doi.org/10.21037/tcr-22-2029>

[^] ORCID: Lorenzo Innocenti, 0000-0001-6492-6951; Maria Isabella Rotondo, 0000-0002-8851-3729; Francescamaria Donati, 0000-0002-0608-8360; Daniela Campani, 0000-0001-5987-734X.

Introduction

Intraductal oncocytic papillary neoplasm (IOPNs) of the pancreas are infrequent tumours, accounting for 4.5% of intraductal pancreatic neoplasms (1). Firstly described in 1996 by Adsay *et al.* (2), these lesions have been recognized as distinct entities by the 2019 World Health Organization (WHO) classification of Digestive System Tumours. Along with intraductal papillary mucinous neoplasm (IPMN) and intraductal tubulopapillary neoplasm (ITPN), IOPNs belong to the category of intraductal pancreatic neoplasms.

Microscopically IOPNs are distinguished from IPMNs and ITPNs by the presence of dysplastic oncocytic elements arranged in frondous papillae.

Given the rarity of this neoplasm, we present two cases of IOPN as well as a review of the recent literature. The peculiarity of the IOPN described in case 1 is the extent of the size of the lesion, reaching a maximum of 24 cm. To the current day, this case accounts for the largest IOPN ever described in the literature. We present the following cases in accordance with the CARE reporting checklist (available at <https://tcr.amegroups.com/article/view/10.21037/tcr-22-2029/rc>).

Highlight box

Key findings

- We describe two patients with IOPN—one accounting for the largest ever described—and provide a brief review of recent discoveries on the subject.

What is known and what is new?

- IOPNs are rare tumours affecting the pancreato-biliary system. Pancreatic IOPNs occur mainly locate in the head and proximal body and their average size is 5.5 cm. Pre-surgical differential diagnosis with IPMNs is challenging and often requires ancillary tests. IOPNs show little tendency to invade surrounding structures and metastasize.
- We describe a case of IOPN measuring 24 cm, the largest case ever described in literature. Despite its remarkable size, the tumour showed little aggressiveness, highlighting the biological peculiarities of IOPNs.

What is the implication, and what should change now?

- Given the rarity of IOPNs, further studies are required for a more precise radiological and pre-surgical identification of these neoplasms.
- A better understand of the biological mechanisms involved in the pathogenesis of these neoplasms is needed.




Figure 1 Case 1: axial T2-weighted MRI image shows the manifestation of IOPN affecting the entire pancreas. Solid vegetations appear hypointense compared to the high intensity of the marked cystic dilatation of the pancreatic ductal system. MRI, magnetic resonance imaging; IOPN, intraductal oncocytic papillary neoplasm.

Case presentation

Case 1

A 70-year-old Italian man presented to the general surgery department of our hospital in 2021, complaining of right abdominal pain radiating to the homolateral testicle. The patient had already been admitted to the emergency room for previous episodes of right renal colics. Ultrasound (US) revealed pyeloectasis and the presence of a large mass located in the mesogastric and anterior epigastric region, requiring additional abdominal computed tomography (CT).

Abdominal CT revealed grade I hydronephrosis with mid-ureteral stone, a possible culprit for the referred symptoms. Pancreatic volume was consistently increased with loss of normal parenchymal lobulation. Magnetic resonance cholangiopancreatography (MRCP) highlighted multiple vegetations protruding into the main and accessory ducts (*Figure 1*). Contrast enhancement was also noted, in support of the proliferative nature of the lesion. The patient was scheduled for surgery, before which a second abdominal CT showed significant enlargement of the gland with involvement of the proximal part of the main pancreatic duct (MPD). Splenic, common hepatic, gastroduodenal arteries and portal confluence were not involved. A first diagnostic hypothesis was of ITPN.

Presurgical laboratory tests showed the following




Figure 2 Case 1: gross appearance of the surgical specimen (left: anterior view; right: transverse section).




Figure 3 Case 1: histological features of IOPN are readily seen (HE, original magnification: $\times 100$). Florid papillary growth and oncocytic morphology are distinctive traits of pancreato-biliary IOPNs (insert: HE, original magnification: $\times 200$). IOPN, intraductal oncocytic papillary neoplasm; HE, haematoxylin-eosin stain.




Figure 4 Case 1: isolate focus of stromal microinvasion was present and extending for an area of less than 0.5 mm (HE, original magnification: $\times 200$). HE, haematoxylin-eosin stain.

results: glucose level of 122 mg/dL [standard value (s.v.), 60–100 mg/dL], aspartate aminotransferase level of 17 IU/L (s.v., 2–31 IU/L), alanine aminotransferase level of 20 (s.v., 2–34 IU/L) and total bilirubin level of 0.23 mg/dL (s.v., 0.50–1.20 mg/dL). Serum level of carbohydrate antigen (CA)19-9 was 23 IU/mL (s.v., 0–27 IU/mL), of carcinoembryonic antigen (CEA) was 1.3 ng/mL (s.v., 0–5 ng/mL) and of CA125 was 11 IU/mL (s.v., 0–27 IU/mL).

The patient underwent total pancreatectomy with segmental duodenectomy and resection of the splenomesenteric portal venous confluence.

Gross examination of the pancreas revealed a 24×9×9 cm solido-cystic neoplasm entirely replacing the parenchyma, partially filled with mucin and with extensive hemorrhagic areas (*Figure 2*). Common bile duct presented a diameter of 1 cm.

Histologically, the lesion was composed of intraductal papillary and cribriform structures lined by highly dysplastic oncocytic cells. The neoplastic elements showed wide, finely granular, eosinophilic cytoplasm and prominent nucleoli (*Figure 3*). Minimal (<5 mm) stromal infiltration was documented (*Figure 4*). Neither lymphatic nor vascular invasion was evident. On immunohistochemical (IHC), neoplastic cells were positive for cytokeratin 7, mucin (MUC)1, MUC5AC (*Figure 5*), MUC6 and HepPar1 (*Figure 6A*), focally positive for CD117(KIT) (*Figure 6B*) and negative for MUC2, CK20, Chromogranin A and Bcl-10. Collateral pancreatic parenchyma showed marked atrophy. Forty-eight regional lymph nodes were uninvolved showing reactive hyperplasia. A final diagnosis of IOPN with minimal stromal invasion was formulated, classified




Figure 5 Case 1: IHC stain for MUC5A (original magnification: $\times 200$). IHC, immunohistochemical.

as pT1a pN0 R0 (3). In 10-month follow-up, the patient completely recovered and did not experience relapse.

Case 2

A 60-year-old Italian man was referred to the general surgery department of our hospital in 2022 with right lumbar pain radiating to the homolateral groin negative to the Giordano manoeuvre. US was not able to evidence the pancreatic gland due to marked meteorism. Clinical history was unremarkable.

Abdominal contrast-enhanced CT revealed an 8.5×7.5 cm mass protruding from the pancreatic tail dislocating the left kidney and the descending colon. The lesion showed a hypodense central portion and 2 to 3 mm-thick walls lined by solid papillary-like projections with marked contrast-enhancement (*Figure 7*). A worrisome feature was the absence of a clear adipose cleavage plane with the left colic flexure. A preliminary diagnosis of degenerated IPMN of the terminal MPD was formulated.

Presurgical laboratory tests showed the following results: glucose level of 104 mg/dL (s.v., 60–100 mg/dL), aspartate aminotransferase level of 20 IU/L (s.v., 2–31 IU/L), alanine aminotransferase level of 42 (s.v., 2–34 IU/L) and total bilirubin level of 0.32 mg/dL (s.v., 0.50–1.20 mg/dL). Serum level determinations of CA19.9, CEA and CA125 were not available.

The patient underwent distal pancreatectomy with splenectomy two weeks after radiological identification.

Gross examination revealed a capsulated $8.5 \text{ cm} \times 8.5 \text{ cm} \times 8 \text{ cm}$ mass located in the pancreatic body at 7.5 cm from surgical margin and communicating with the MPD. Cut surface was cystic and showed the presence of a mucinous content.

Microscopically, the lesion was composed of a papillary and cribriform proliferation involving secondary ducts. The epithelial component displayed variable grades of dysplasia and typical oncocytic features. A small focus ($<5 \text{ mm}$) of stromal infiltration without lympho-vascular invasion was also noted. Forty regional lymph nodes demonstrated reactive hyperplasia.

IHC staining revealed positivity for cytokeratin 7, MUC5AC, MUC1 and MUC6; focal positivity for CD117 and HepPar1 and negativity for MUC2 and CK20. Collateral pancreatic parenchyma showed variable degrees of adipous involution.

The final diagnosis was determined to be IOPN with minimal stromal invasion, classified as pT1a N0 R0 (3).

After a 10-month follow-up, the patient has completely recovered and has not experienced relapse.

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Declaration of Helsinki (as revised in 2013). Written informed consent were obtained from the patients for publication of these case reports and accompanying images. A copy of the written consent is available for review by the editorial office of this journal.

Discussion

IOPNs of the pancreas are a relatively new entity within the family of intraductal papillary neoplasms. 2019 WHO classification of Digestive System Tumours raised IOPNs to a distinct nosological entity, in consideration of recent molecular and clinico-pathological data revealing the rather substantial differences between IOPNs and IPMNs.

Despite their rarity, a number of studies have been written on IOPNs since 1996 and a first systematic review by Wang *et al.* was published in 2019, collecting clinico-pathological data relative to 66 cases of IOPN and highlighting the need for large-scale cohort studies in order to strengthen our understanding of IOPNs (4).

In this case report, a brief review of the literature published from 2019 to date is presented. Only English written papers were included in the collection, impairing the statistical accuracy of data. A total of 80 IOPNs from 9 studies have been collected after the publication by Wang *et al.* clinico-pathological data for each case were not entirely available; a comprehensive list is available in *Table 1*.

Age at presentation of IOPNs ranges from 36 to 84 years, occurring equally in males and females. Diagnosis is usually subsequent to unspecific abdominal symptoms or concurrent




Figure 6 Case 1: (A) IHC stain for HepPar1 (original magnification: $\times 400$); (B) IHC stain for CD117 (original magnification: $\times 200$). IHC, immunohistochemical.




Figure 7 Case 2: CT scan shows the manifestation of IOPN as a heterogeneous macrocystic lesion in the tail of the pancreas, without parietal calcifications. Portal venous CT demonstrates an irregularly thick-walled cystic lesion with hyperdense solid papillary vegetations. CT, computed tomography; IOPN, intraductal oncocytic papillary neoplasm.

to imaging tests carried out for other reasons. Recurrent pancreatitis or painless jaundice can in rare case represent the onset manifestations. In a series of 182 pancreatic intraductal papillary neoplasms, including 3 IOPNs, Tanaka *et al.* found no correlation between oncocytic features and acute pancreatitis. On the other hand, intestinal and pancreato-biliary type IPMNs showed 22.4% and 35.7% incidence rates, respectively (5).

Available data collected from 2019 show that approximately half of the cases (22/43; 51.2%) were located in the head and proximal body and a slightly lesser number involved the distal body and tail (20/43; 46.5%).

Average size of IOPNs is 5.5 cm and tend to be slightly larger than IPMNs (1). The 54 cases collected from recent literature show a mean diameter of 4.8 cm.

The two cases collected from our institution fall within the expected age of diagnosis and show a prototypical clinico-pathological picture. In case 1 the diagnosis was subsequent to an unrelated renal colic, leading to the identification of the pancreatic lesion. Remarkably, at the time of diagnosis the normal pancreatic parenchyma was almost completely effaced by the florid IOPN growth. Diffuse involvement of the pancreas had already been described in the past, although it appears to be a rare circumstance.

CA19.9 and CEA serum levels are widely used in the preoperative setting of IPMNs. A rise in serum titres represents a worrisome feature suggestive of malignant transformation. Unlike IPMNs, IOPNs do not appear to be correlated with a rise in serological markers. Current preoperative tests are thus not useful for estimating the risk of degeneration. Case 1 was tested for tumour markers and CA19.9 and CEA levels were within the normality range.

Radiological diagnosis of IOPNs is exceptional, as both IPMNs and ITPNs appear as cystic dilations of the pancreatic ducts. Unlike IPMNs, ITPNs rarely display an evident cystic component and tend to present as solid masses filling the MPD (12). The presence of complex and arborizing papillae can represent a diagnostic hint for IOPN.

The high vascularity of IOPNs is responsible for the intense uptake of iodine and gadolinium-based contrast media, commonly interpreted as the presence of a solid component within the lesion.

The increased number of mitochondria inside oncocytes is accountable for the intense metabolic activity of oncocytic neoplasms. On positron emission tomography

Table 1 Comprehensive list of cases of IOPN described in literature

Reference	No. of cases	Age (years)	Sex	Tumor size (mm)	Stromal invasion	Topography	LVI	PNI	LN status	Follow-up
Wang (4)	66	n.a.	M:F =1:1	55	27/66 cases	n.a.	n.a.	n.a.	6/55	Alive without disease: 6/55 Dead of disease: 4/50 Dead of perioperative complications: 9/50
Tanaka (5)	3	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Hirabayashi (6)	11	60.6 (mean)	n.a.	45.5 (mean)	9/11 cases	n.a.	n.a.	n.a.	n.a.	n.a.
Mattiolo (7)	17	n.a.	n.a.	n.a.	2/17 cases	n.a.	n.a.	n.a.	n.a.	n.a.
Vyas (8)	2	63	M	70	Present	Head	n.a.	n.a.	n.a.	n.a.
		36	M	45	Absent	Head	n.a.	n.a.	n.a.	n.a.
Kobayashi (9)	6	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Singhi (10)	20	43	F	34	Absent	Body	n.a.	n.a.	n.a.	n.a.
		25	M	51	Present	Body	n.a.	n.a.	n.a.	n.a.
		51	F	47	Absent	Body	n.a.	n.a.	n.a.	n.a.
		67	M	45	Absent	Head	n.a.	n.a.	n.a.	n.a.
		54	M	37	Present	Head	n.a.	n.a.	n.a.	n.a.
		48	F	45	Present	Body	n.a.	n.a.	n.a.	n.a.
		57	M	53	Present	Tail	n.a.	n.a.	n.a.	n.a.
		64	M	70	Present	Head	n.a.	n.a.	n.a.	n.a.
		27	M	45	Absent	Body	n.a.	n.a.	n.a.	n.a.
		72	M	60	Present	Head	n.a.	n.a.	n.a.	n.a.
		47	M	25	Present	Head	n.a.	n.a.	n.a.	n.a.
		74	M	60	Present	Head + body	n.a.	n.a.	n.a.	n.a.
		52	F	25	Absent	Tail	n.a.	n.a.	n.a.	n.a.
		65	M	82	Absent	Tail	n.a.	n.a.	n.a.	n.a.
		63	M	20	Absent	Head	n.a.	n.a.	n.a.	n.a.
		64	M	60	Present	Head	n.a.	n.a.	n.a.	n.a.
		57	M	35	Absent	Head	n.a.	n.a.	n.a.	n.a.
		67	M	25	Present	Tail	n.a.	n.a.	n.a.	n.a.
		50	F	65	Present	Body	n.a.	n.a.	n.a.	n.a.
		75	F	51	Absent	Head	n.a.	n.a.	n.a.	n.a.

Table 1 (continued)

Table 1 (continued)

Reference	No. of cases	Age (years)	Sex	Tumor size (mm)	Stromal invasion	Topography	LVI	PNI	LN status	Follow-up
Nakahodo (11)	18	44	M	100	Present	Body + tail	n.a.	n.a.	n.a.	n.a.
		45	M	15	Present	Head	n.a.	n.a.	n.a.	n.a.
		47	F	40	Present	Body + tail	n.a.	n.a.	n.a.	n.a.
		58	F	30	Present	Head	n.a.	n.a.	n.a.	n.a.
		59	F	30	Absent	Head	n.a.	n.a.	n.a.	n.a.
		61	F	25	Absent	Body + tail	n.a.	n.a.	n.a.	n.a.
		61	M	35	Absent	Head	n.a.	n.a.	n.a.	n.a.
		62	M	75	Absent	Head	n.a.	n.a.	n.a.	n.a.
		64	M	12	Absent	Body + tail	n.a.	n.a.	n.a.	n.a.
		67	M	30	Present	Head	n.a.	n.a.	n.a.	n.a.
		69	F	22	Absent	Head	n.a.	n.a.	n.a.	n.a.
		69	F	30	Present	Head	n.a.	n.a.	n.a.	n.a.
		75	M	50	Present	Body + tail	n.a.	n.a.	n.a.	n.a.
		76	F	70	Present	Head	n.a.	n.a.	n.a.	n.a.
		79	F	50	Absent	Body + tail	n.a.	n.a.	n.a.	n.a.
		80	M	22	Absent	Head	n.a.	n.a.	n.a.	n.a.
		82	F	25	Present	Body + tail	n.a.	n.a.	n.a.	n.a.
		82	M	26	Absent	Body + tail	n.a.	n.a.	n.a.	n.a.
Innocenti (present study)	2	75	M	240	Present	Diffuse	Absent	Absent	N0	Alive
		61	M	90	Present	Tail	Absent	Absent	N0	Alive

IOPN, intraductal oncocytic papillary neoplasm; LVI, lymphovascular invasion; PNI, perineurial invasion; LN, lymph node; n.a., not available; M, male; F, female.

(PET) scan, IOPNs are characterized by a marked uptake of ^{18}F -fluorodeoxyglucose (FDG) (13). To the unaware, high standardized uptake value (SUV) values could be inadvertently interpreted as sign of invasion, prompting to an aggressive surgical approach (14).

Fine-needle aspiration (FNA) has shown to be a powerful tool in the preoperative diagnosis of IOPN. A study from Reid *et al.* described 5 cases of IOPN preoperatively diagnosed via FNA; 4 out of 5 cases provided a hypercellular sample and 2 cases showed the presence of thick extracellular mucin (15).

Cytological differential diagnosis of IOPN focuses on oncocytic-like neoplasms such as oncocytic pancreatic neuroendocrine tumours (PanNETs), acinic cell carcinomas, ITPNs and metastatic carcinomas with oncocytic features.

Oncocytic PanNETs are aggressive variants characterized by large cells with eosinophilic cytoplasm, smooth nuclear contours and prominent eccentric nucleoli (16). IHC positivity for neuroendocrine markers rules out IOPNs.

Acinic neoplasms can cytologically resemble IOPNs, but the presence of brisk mitotic activity along with a lack of mucin and papillary structures point towards pancreatic acinic adenocarcinoma (15). Acinic differentiation can be confirmed via IHC with Bcl-10 and trypsin.

ITPNs pose a difficult differential diagnosis in consideration of their highly dysplastic appearance and presence of prominent nucleoli. Absence of the typical granular eosinophilic cytoplasm and almost complete absence of mucin are more suggestive of ITPN (17).

IOPNs grossly present under the form of complex solid-

cystic masses, frequently located in the MPD. IOPNs rarely appear as purely cystic lesions and usually display a lesser degree of both extracellular and intracellular mucin production. On both macroscopic and microscopic grounds, mucin content appears to be a distinguishing feature between IOPNs and IPMNs. Enlarged MPD filled with mucus is a typical IPMN endoscopic finding and has not been reported in neither IOPNs nor ITPNs (18).

IOPNs are characterized by florid papillary projections protruding into the duct lumen, with variable coalescence into solid areas. The fibrovascular stalks of IOPN papillae are usually scant and can occasionally display areas of hyalinization. Hirabayashi *et al.* described the stromal characteristics of 11 cases of IOPN along with 168 cases of IPMN. The presence of hyalinised fibrovascular cores was much more commonly reported in IOPNs (45.5%) compared to IPMNs (1.2%). Hyalinized stroma showed IHC positivity for collagen and little to no positivity for laminin (6).

On IHC, IOPNs show diffuse positivity for MUC1 (EMA) and MUC6, similarly to ITPNs. MUC5AC and MUC2 are usually confined to the goblet cell population. Oncocytic elements show a typical granular positivity for HepPar1.

Mattiolo *et al.* has investigated CD117 (c-KIT) expression in a cohort of 111 intraductal papillary neoplasms, including 17 IOPNs. CD117 positivity was able to distinguish IOPNs from all different IPMN subtypes, the former characterized by stronger and more diffuse pattern of expression (7).

Further, IHC peculiarities were noted by Basturk *et al.*, such as higher rates of mesothelin and lower rates of claudin-4 expression if compared to IPMNs (19).

IOPNs display stromal invasion in up to 30% of cases (8,19). Out of the 71 available cases described from 2019 to date, 34 (47.9%) showed at least focal areas of stromal infiltration. Attention should be paid in distinguishing entrapped epithelial cells within tumour pseudocapsule from true stromal invasion.

Despite the presence of invasion, aggressive biological behaviour is uncommon. In a series of 55 IOPN cases described by Wang, 10 patients presented with either nodal, hepatic or cerebral metastases (4).

Marchegiani *et al.* described 18 cases of IOPN with specific focus to follow-up. Out of 18 patients, 6 displayed areas of overt invasive carcinoma. Recurrence rates at 5 and 10 years were 31% and 46% respectively, hinting at a possible role of field cancerization. Patients with evidence

of recurrence undergoing complete pancreatectomy did not experience further relapses (20).

Genetic advances in the understanding of pancreatic papillary neoplasms reduced the ambiguity with regard to the nomenclature and the biology of such lesions.

More than 90% of IPMNs are known to harbour *KRAS* point mutations. Other commonly mutated genes are *GNAS* (40–60%), *RNF43* (25%) and *TP53* (10%) (21).

The genomic landscape of IOPNs substantially differs from that of IPMNs and displays a variety of alternative molecular prints. Basturk *et al.* demonstrated that none of their 22 IOPN cases harboured *KRAS* and *GNAS* mutations (19).

Kobayashi *et al.* extensively studied molecular pathways involved in the development of pancreatic papillary intraductal neoplasms; 2 of the 6 described IOPNs cases showed *adenomatous polyposis coli* (*APC*) mutations and presenting higher histological dysplasia if compared to *APC* wild-type IOPNs (9). Gastric, intestinal and pancreato-biliary IPMNs showed significantly lower rates of *APC* mutations.

The discovery of recurrent kinase gene rearrangements in IOPNs revived the interest in the biology of these entities.

Singhi *et al.* revealed the ubiquitous presence of fusion genes involving *PRKACA* and *PRKACB* sequences in a series of 20 IOPNs via RNA-targeted sequencing. None of the 3 described biliary IOPNs showed involvement of such genes, remarking the molecular differences between these lesions. Transcriptome sequencing identified 3 mutually exclusive fusion genes: *ATP1B1-PRKACB*, *DNAJB1-PRKACA* and *ATP1B1-PRKACA* recurring with a frequency of 50%, 30% and 20% respectively (10).

The increased transcription activity of *DNAJB1* and *ATP1B1* promoters elicit an over-expression of *PRKACA* and *PRKACB* sequences, ultimately leading increased protein kinase A (PKA) function.

In 2014, Honeyman *et al.* had already reported the presence of *DNAJB1-PRKACA* fusion in fibrolamellar hepatocarcinoma (22).

Vyas *et al.* also found *DNAJB1-PRKACA* and *ATP1B1-PRKACA* to be common mutations in pancreato-biliary IOPNs. According to the authors, the cytological similarities between fibrolamellar hepatocarcinoma and IOPNs could find their ground at a biochemical level, being PKA notoriously active on several substrates within the mitochondrial matrix. According to this hypothesis, the subsequent mitochondrial hyperplasia would be responsible

of the oncocytic appearance of both tumour cell types (8).

Nakahodo *et al.* described over-expression of follistatin-coding mRNA in IOPNs. All of the 22 pancreato-biliary IOPNs showed IHC positivity for follistatin. Decreased apoptotic activity in IOPN cells—demonstrated by low expression of cleaved caspase 3 (CC3) on IHC—represents another interesting molecular finding (11).

Our understanding of IOPNs is growing but larger cohorts are needed in order to collect uniform data. Possible differences could lie between pure IOPNs and combined IOPNs and further studies will require to take this difference into consideration, especially if focusing on the biology of this entity.

Acknowledgments

Funding: This study was supported by Pisa University funds.

Footnote

Reporting Checklist: The authors have completed the CARE reporting checklist. Available at <https://tcr.amegroups.com/article/view/10.21037/tcr-22-2029/rc>

Peer Review File: Available at <https://tcr.amegroups.com/article/view/10.21037/tcr-22-2029/prf>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://tcr.amegroups.com/article/view/10.21037/tcr-22-2029/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Declaration of Helsinki (as revised in 2013). Written informed consent were obtained from the patients for publication of these case reports and accompanying images. A copy of the written consent is available for review by the editorial office of this journal.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-

commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. D'Onofrio M, De Robertis R, Tinazzi Martini P, et al. Oncocytic Intraductal Papillary Mucinous Neoplasms of the Pancreas: Imaging and Histopathological Findings. *Pancreas* 2016;45:1233-42.
2. Adsay NV, Adair CE, Heffess CS, et al. Intraductal oncocytic papillary neoplasms of the pancreas. *Am J Surg Pathol* 1996;20:980-94.
3. Amin MB, Edge SB, Greene FL, et al. editors. AJCC cancer staging manual. 8th edition. Chicago, IL, USA: Springer, 2017.
4. Wang T, Askan G, Adsay V, et al. Intraductal Oncocytic Papillary Neoplasms: Clinical-Pathologic Characterization of 24 Cases, With An Emphasis on Associated Invasive Carcinomas. *Am J Surg Pathol* 2019;43:656-61.
5. Tanaka T, Masuda A, Sofue K, et al. Acute pancreatitis in intraductal papillary mucinous neoplasms correlates with pancreatic volume and epithelial subtypes. *Pancreatol* 2021;21:138-43.
6. Hirabayashi K, Kawanishi A, Morimachi M, et al. Hyalinized stroma is a characteristic feature of pancreatic intraductal oncocytic papillary neoplasm: An immunohistochemical study. *Ann Diagn Pathol* 2020;49:151639.
7. Mattiolo P, Hong SM, Paolino G, et al. CD117 Is a Specific Marker of Intraductal Papillary Mucinous Neoplasms (IPMN) of the Pancreas, Oncocytic Subtype. *Int J Mol Sci* 2020;21:5794.
8. Vyas M, Hechtman JF, Zhang Y, et al. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. *Mod Pathol* 2020;33:648-56.
9. Kobayashi T, Omori Y, Ono Y, et al. Pathways for the development of multiple epithelial types of intraductal papillary mucinous neoplasm of the pancreas. *J Gastroenterol* 2021;56:581-92.
10. Singhi AD, Wood LD, Parks E, et al. Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas and Bile Duct. *Gastroenterology* 2020;158:573-82.e2.
11. Nakahodo J, Fukumura Y, Saito T, et al. Upregulation

- of follistatin and low apoptotic activity in intraductal oncocytic papillary neoplasm of the pancreatobiliary system. *Sci Rep* 2020;10:8179.
12. Zhang J, Ren S, Wang J, et al. Imaging findings of intraductal tubulopapillary neoplasm (ITPN) of the pancreas: Two case reports and literature review. *Medicine (Baltimore)* 2019;98:e14426.
 13. Noji T, Kondo S, Hirano S, et al. Intraductal oncocytic papillary neoplasm of the pancreas shows strong positivity on FDG-PET. *Int J Gastrointest Cancer* 2002;32:43-6.
 14. Fischer MA, Donati O, Heinrich S, et al. Intraductal oncocytic papillary neoplasm of the pancreas: a radio-pathological case study. *JOP* 2010;11:49-54.
 15. Reid MD. Cytologic Assessment of Cystic/Intraductal Lesions of the Pancreatobiliary Tract. *Arch Pathol Lab Med* 2022;146:280-97.
 16. Xue Y, Reid MD, Pehlivanoglu B, et al. Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification. *Endocr Pathol* 2020;31:239-53.
 17. Tajima S. Intraductal tubulopapillary neoplasm of the pancreas suspected by endoscopic ultrasonography-fine-needle aspiration cytology: Report of a case confirmed by surgical specimen histology. *Diagn Cytopathol* 2015;43:1003-6.
 18. Reid MD, Stallworth CR, Lewis MM, et al. Cytopathologic diagnosis of oncocytic type intraductal papillary mucinous neoplasm: Criteria and clinical implications of accurate diagnosis. *Cancer Cytopathol* 2016;124:122-34.
 19. Basturk O, Chung SM, Hruban RH, et al. Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas. *Virchows Arch* 2016;469:523-32.
 20. Marchegiani G, Mino-Kenudson M, Ferrone CR, et al. Oncocytic-type intraductal papillary mucinous neoplasms: a unique malignant pancreatic tumor with good long-term prognosis. *J Am Coll Surg* 2015;220:839-44.
 21. Visani M, Acquaviva G, De Leo A, et al. Molecular alterations in pancreatic tumors. *World J Gastroenterol* 2021;27:2710-26.
 22. Honeyman JN, Simon EP, Robine N, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. *Science* 2014;343:1010-4.

Cite this article as: Innocenti L, Rotondo MI, Donati F, Boggi U, Campani D. Intraductal oncocytic papillary neoplasm (IOPN): two case reports and review of the literature. *Transl Cancer Res* 2023;12(3):663-672. doi: 10.21037/tcr-22-2029